|
|
Post by cellvestor on Feb 8, 2016 21:48:53 GMT
Just happen to be looking around OCATA's webpage and saw that the P 1/2 Trails for MMD was updated as of February 4, 2016 at ClinicalTrials.gov and is currently recruiting participants. Why would OCATA be using their resources to start a phase 1/2 trail with Dr. Schwartz at UCLA when they should be starting the phase 2 for AMD?
|
|
|
|
Post by imz72 on Feb 8, 2016 22:18:39 GMT
|
|
|
|
Post by vzveteran on Feb 8, 2016 22:21:11 GMT
The bar was set too high remember? I wonder if they gave up on PhII for now. We don't know because the Company keeps us in the dark about everything except the offer.
|
|
|
|
Post by selluwud on Feb 8, 2016 22:21:57 GMT
GR told us from the beginning that Jules Stein was looking for funding to proceed, Ocat was not running the trial and didn't apply for the IND.
|
|
